European Archives - Page 66 of 1659 - European Medical Journal

Hydrophilic Catheters: PVP Concerns

Intermittent catheterisation (IC) is practised by patients with a variety of conditions that can affect bladder function, including spinal…

Optimising Diagnosis and Management of Obstructive Müllerian Anomalies

Müllerian anomalies are a group of anomalies of the reproductive tract resulting from incomplete or atypical development of the Müllerian…

Apparent Drug-Induced Anaphylaxis from Semen

Hypersensitivity reactions associated with intimate sexual activity are probably underdiagnosed and frequently go undiagnosed. Reported…

Inflammatory Biomarkers in Individuals with SCD in Kano

Sickle cell disease (SCD) is a genetic disease that is due to single nucleotide polymorphism of the β-haemoglobin gene in the first exon…

Intratesticular Platelet-Rich Plasma in Severe Male Factor Infertility and Non-obstructive Azoospermia

Male factor infertility contributes to approximately half of all infertility cases, affecting one in six couples worldwide.1 Azoospermia…

Vomiting Induced Cartoid Artery Dissection Caused by Hypermobile Ehlers-Danlos Syndrome

Carotid artery dissection (CAD) can arise from traumatic, spontaneous, and iatrogenic causes. Spontaneous CAD is generally rare, but a…

Person holding model stormach

New Microscope Offers Hope for People with Inflammatory Bowel Disease

A new super-resolution microscope could help scientists better understand IBD and identify potential targets for treatment.

Closeup of the Novo Nordisk sign outside its office in Fremont, California. Novo Nordisk is a Danish multinational pharmaceutical company headquartered in Bagsværd

Novo Nordisk rebrands to the single name 'Novo'

The change to ‘Novo’ follows two years of share-price declines, a change of leadership and falling market share.

targeted therapy

Targeted Therapy Improves Outcomes in HER2 Lung Cancer: WCLC 2026

DESTINY-Lung04 data show trastuzumab deruxtecan improved progression-free survival and response rates in first-line HER2-mutant NSCLC.

exons and introns

Amivantamab Extends Survival in Advanced NSCLC: WCLC 2026

Final PAPILLON data showed that first-line amivantamab chemotherapy extended median overall survival by more than 6 months in advanced EGFR Ex20ins NSCLC.